Abstract
Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [124I] for a proof of concept study to assess the diagnostic accuracy of [124I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [124I]sodium iodide and meta-trimethylsilylbenzylguanidine. [124I]mIBG was produced in 62–70 % radioiodide incorporation yield from [124I]sodium iodide. The average amount of formulated [124I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol−1 (range 1.8–5.9 TBq μmol−1) at end of synthesis.
Author supplied keywords
Cite
CITATION STYLE
Green, M., Lowe, J., Kadirvel, M., McMahon, A., Westwood, N., Chua, S., & Brown, G. (2017). Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma. Journal of Radioanalytical and Nuclear Chemistry, 311(1), 727–732. https://doi.org/10.1007/s10967-016-5073-1
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.